drugset / Trial / NCT00634920
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate if early conversion to everolimus from cyclosporine in de novo renal transplant recipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy
Timeline
- Start
- 2008-03
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Subject | Everolimus | Small molecule | 4 mg | Oral |
| Background | Basiliximab | Monoclonal antibody | 20 mg | — |
| Background | Corticosteroids | Unknown | — | — |
| Background | Enteric Coated Mycophenolate Sodium (EC-MPS) | Unknown | 1080 mg | — |
| Background | Enteric Coated Mycophenolate Sodium (EC-MPS) | Unknown | 1440 mg | — |